MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.

Huadong Zhao, Guoqiang Bao(Qinghai University), Shixiong Lei(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Qiu(Beijing Tongren Hospital), Xiaomin Liu(Shanghai University), Chong Chen(Sun Yat-sen University), Hang Guo(Second Affiliated Hospital of Jilin University), Fan Dong(Zhejiang Chinese Medical University), Li Gong(Xi'an Medical University), Qike Huang(Xijing Hospital), Jianguo Lu(Air Force Medical University), Haili Tang(Tang Du Hospital)
PubMed
January 1, 2016
Cited by 31


Related Papers